| Defining the relationship between COPD and CVD: what are the implications for clinical practice? |
29 |
| Role of immune-checkpoint inhibitors in lung cancer |
18 |
| Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness |
15 |
| Biomarkers in the diagnosis of pleural diseases: a 2018 update |
12 |
| Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience |
12 |
| Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience |
11 |
| Fatigue is highly prevalent in patients with COPD and correlates poorly with the degree of airflow limitation |
11 |
| How will telemedicine change clinical practice in chronic obstructive pulmonary disease? |
11 |
| Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience |
10 |
| The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy |
9 |
| New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1 |
9 |
| The 1-minute sit-to-stand test to detect exercise-induced oxygen desaturation in patients with interstitial lung disease |
9 |
| Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease |
8 |
| Using step counters to promote physical activity and exercise capacity in patients with chronic obstructive pulmonary disease: a meta-analysis |
7 |
| High-flow nasal cannula oxygen therapy to treat acute respiratory failure in patients with acute exacerbation of idiopathic pulmonary fibrosis |
6 |
| Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience |
6 |
| Triple therapy for COPD: a crude analysis from a systematic review of the evidence |
6 |
| Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma |
6 |
| Asthma-COPD overlap: identification and optimal treatment |
6 |
| Safety of tiotropium in patients with asthma |
5 |
| Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study |
5 |
| Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records |
5 |
| DT-0111: a novel drug-candidate for the treatment of COPD and chronic cough |
5 |
| Association between tumor necrosis factor-alpha and chronic obstructive pulmonary disease: a systematic review and meta-analysis |
5 |
| Long-term follow up after endoscopic valve therapy in patients with severe emphysema |
5 |
| What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape |
5 |
| Advances in proton therapy in lung cancer |
5 |
| Fiducial marker placement with electromagnetic navigation bronchoscopy: a subgroup analysis of the prospective, multicenter NAVIGATE study |
5 |
| Clinical outcomes of patients receiving prolonged extracorporeal membrane oxygenation for respiratory support |
4 |
| Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor |
4 |
| Autophagy and pulmonary disease |
4 |
| Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases |
4 |
| Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management |
4 |
| Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects |
3 |
| Preclinical and clinical studies of smoke-inhalation-induced acute lung injury: update on both pathogenesis and innovative therapy |
3 |
| Duration of treatment with inhaled corticosteroids in nonasthmatic eosinophilic bronchitis: a randomized open label trial |
3 |
| Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial |
3 |
| Characteristics and outcome of patients set up on high-flow oxygen therapy at home |
3 |
| Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study |
3 |
| Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience |
3 |
| Tailored combined cytomegalovirus management in lung transplantation: a retrospective analysis |
3 |
| Efficacy and safety profile of autologous blood versus talc pleurodesis for malignant pleural effusion: a randomized controlled trial |
3 |
| Contemporary optimized practice in the management of pulmonary sarcoidosis |
3 |
| Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review |
3 |
| Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting beta 2-agonists delivered via a pressurized metered-dose inhaler |
3 |
| Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials |
3 |
| A review of the in vitro and in vivo valved holding chamber (VHC) literature with a focus on the AeroChamber Plus Flow-Vu Anti-static VHC |
3 |
| Contemporary best practice in the management of malignant pleural effusion |
3 |
| Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study |
3 |
| Inhalation with intravenous loading dose of colistin in critically ill patients with pneumonia caused by carbapenem-resistant gram-negative bacteria |
3 |
